20 related articles for article (PubMed ID: 33711392)
1. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial.
Kudrow D; Cady RK; Allan B; Pederson SM; Hirman J; Mehta LR; Schaeffler BA
BMC Neurol; 2021 Mar; 21(1):126. PubMed ID: 33740902
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.
Weisel K; Berger S; Thorn K; Taylor PC; Peterfy C; Siddall H; Tompson D; Wang S; Quattrocchi E; Burriss SW; Walter J; Tak PP
Arthritis Res Ther; 2021 Mar; 23(1):85. PubMed ID: 33726834
[TBL] [Abstract][Full Text] [Related]
3. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach.
DuMond B; Patel V; Gross A; Fung A; Weber S
J Oncol Pharm Pract; 2021 Jul; 27(5):1214-1221. PubMed ID: 33719721
[TBL] [Abstract][Full Text] [Related]
4. Familial hemiplegic migraine type 2 due to a novel missense mutation in ATP1A2.
Antonaci F; Ravaglia S; Grieco GS; Gagliardi S; Cereda C; Costa A
J Headache Pain; 2021 Mar; 22(1):12. PubMed ID: 33711927
[TBL] [Abstract][Full Text] [Related]
5. Results from two-year rodent oral carcinogenicity studies of cizolirtine, a substance-P and calcitonin gene-related peptide release modulator.
Guzmán A; Tortajada A; Marín AP; Vila C; Encina G
Regul Toxicol Pharmacol; 2022 Jul; 132():105182. PubMed ID: 35490976
[TBL] [Abstract][Full Text] [Related]
6. The novel analgesic, cizolirtine, inhibits the spinal release of substance P and CGRP in rats.
Ballet S; Aubel B; Mauborgne A; Poliénor H; Farré A; Cesselin F; Hamon M; Bourgoin AS
Neuropharmacology; 2001 Mar; 40(4):578-89. PubMed ID: 11249967
[TBL] [Abstract][Full Text] [Related]
7. Toxicology and carcinogenesis studies of 3,3',4,4'-tetrachloroazobenzene (TCAB) (CAS No. 14047-09-7) in Harlan Sprague-Dawley rats and B6C3F1 mice (gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2010 Nov; (558):1-206. PubMed ID: 21383777
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the Genotoxic Potential of Cizolirtine a Substance-P and Calcitonin Gene-Related Peptide Release Modulator.
Fernández de Henestrosa AR; Marín AP; Tortajada A; Vila C; Guzmán A
Drug Res (Stuttg); 2021 Feb; 71(2):73-82. PubMed ID: 33147634
[TBL] [Abstract][Full Text] [Related]
9. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
10. Toxicology and carcinogenesis studies of androstenedione (CAS No. 63-05-8) in F344/N rats and B6C3F1 mice (gavage studies).
Natl Toxicol Program Tech Rep Ser; 2010 Sep; (560):1, 7-31,33-171 passim. PubMed ID: 21037592
[TBL] [Abstract][Full Text] [Related]
11. Twenty six-week repeat dose oral rat toxicity study of cizolirtine, a substance-P and calcitonin gene-related peptide release modulator.
Guzmán A; Encina G; Fernández de Henestrosa AR; Vila C; Tortajada A; Marín AP
Regul Toxicol Pharmacol; 2021 Jun; 122():104916. PubMed ID: 33711392
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
